Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Investigations of the Preclinical Stage of Alzheimer’s Disease

Investigations of the Preclinical Stage of Alzheimer’s Disease

Monday, January 8, 2018

Corwin Hall
Manhattan Eye Ear and Throat Hospital
210 East 64th Street
New York, NY 10065

Neuropathological changes associated with late onset Alzheimer’s disease (AD) are thought to develop at least a decade prior to symptom onset.  Successful interventions designed to alter these early neuropathological changes during the preclinical stage can increase the probability of delaying or preventing the onset of AD. This presentation will discuss three topics based on a series of studies conducted on healthy elders at risk for developing AD. The first topic will report the results of a 5-year longitudinal functional and structural neuroimaging and neuropsychological study comparing cognitively intact elders with and with the APOE e4 allele. The second topic will highlight a series of studies examining the interaction between physical activity levels and MRI/neuropsychological changes as a function of APOE e4 status.  This discussion will also describe a newly funded NIA translational grant (humans and mice subprojects) that will examine the role of immunological factors that mediate AD neuroprotection with exercise (IMMUNE-AD project).  Finally, the third topic will discuss the utility of a battery of self-administered, iPad-based, computerized cognitive tests for use in mass screening of healthy elders in the primary care clinical setting.  This approach is based on longitudinal neuropsychological studies that document a long period of gradual cognitive decline in episodic memory as well as non-memory domains during the preclinical stage of AD.

Registration information at 


Stephen M. Rao, PhD, Cleveland Clinic
Stephen M. Rao, PhD, Cleveland Clinic